Hepatitis C Combination Therapy - Cubist Pharmaceuticals Reports Results From Phase 2 Study Hepex-B(TM), Which Was Licensed From XTLbio

Cubist Pharmaceuticals Reports Results From Phase 2 Study Hepex-B(TM), Which Was Licensed From XTLbio
[Press Release] PR Newswire via Yahoo! Finance - Dec 21 11:50 PM
XTL Biopharmaceuticals Ltd. announces that Cubist Pharmaceuticals, Inc. today provided data from a recently concluded Phase 2 study of HepeX-B which was licensed to Cubist by XTLbio in 2004.Save to My Web

Texas Scientists Discover How A Hepatitis C Protein Promotes Liver Cancer
Science Daily - Dec 06 6:01 AM
Scientists at the University of Texas Medical Branch at Galveston have identified a key biochemical connection between the hepatitis C virus and liver cancer.Save to My Web

XTL Biopharmaceuticals Announces Appointment of Ron Bentsur As Chief Executive Officer
RedNova - Jan 03 3:19 AM
REHOVOT, Israel, January 3 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals, Ltd. ("XTLbio") , a biopharmaceutical company developing drugs against hepatitis, announced today the appointment of Ron Bentsur as Chief Executive Officer of the Company. Ron Bentsur is based in the US.Save to My Web